Brokerages Set Krystal Biotech, Inc. (NASDAQ:KRYS) Price Target at $365.40

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) have earned a consensus recommendation of “Moderate Buy” from the thirteen ratings firms that are covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $365.40.

A number of equities analysts have weighed in on KRYS shares. Jefferies Financial Group reiterated a “buy” rating and set a $474.00 price objective on shares of Krystal Biotech in a research note on Monday, July 13th. Bank of America upped their target price on Krystal Biotech from $364.00 to $396.00 and gave the stock a “buy” rating in a research note on Tuesday, July 14th. Evercore reaffirmed an “outperform” rating and set a $300.00 target price on shares of Krystal Biotech in a report on Tuesday, May 5th. Chardan Capital raised Krystal Biotech to a “strong-buy” rating in a report on Monday, August 3rd. Finally, HC Wainwright upped their price objective on Krystal Biotech from $310.00 to $361.00 and gave the stock a “buy” rating in a research report on Tuesday, June 16th.

Krystal Biotech Price Performance

KRYS stock opened at $351.46 on Monday. The company has a market capitalization of $10.40 billion, a P/E ratio of 44.04 and a beta of 0.53. Krystal Biotech has a 12 month low of $136.73 and a 12 month high of $382.54. The firm’s fifty day simple moving average is $348.64 and its 200-day simple moving average is $304.39.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, August 3rd. The company reported $1.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.70 by $0.09. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. The firm had revenue of $119.22 million during the quarter, compared to analysts’ expectations of $120.93 million. As a group, sell-side analysts forecast that Krystal Biotech will post 7.48 earnings per share for the current year.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, EVP John Charles Thomas sold 1,000 shares of Krystal Biotech stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $347.27, for a total value of $347,270.00. Following the completion of the transaction, the executive vice president owned 1,000 shares of the company’s stock, valued at approximately $347,270. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the sale, the insider directly owned 1,378,155 shares in the company, valued at approximately $424,623,337.05. The trade was a 1.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 51,000 shares of company stock worth $16,278,020. 13.10% of the stock is owned by company insiders.

Institutional Trading of Krystal Biotech

Several institutional investors have recently bought and sold shares of the business. Silvant Capital Management LLC purchased a new position in shares of Krystal Biotech during the 2nd quarter valued at approximately $30,000. Western Wealth Management LLC purchased a new stake in Krystal Biotech in the 1st quarter worth $34,000. Greenline Wealth Management LLC purchased a new stake in Krystal Biotech in the 4th quarter worth $34,000. Danske Bank A S acquired a new position in Krystal Biotech during the third quarter worth $35,000. Finally, UMB Bank n.a. raised its position in Krystal Biotech by 34.6% during the fourth quarter. UMB Bank n.a. now owns 144 shares of the company’s stock worth $36,000 after acquiring an additional 37 shares during the period. 86.29% of the stock is owned by institutional investors and hedge funds.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.